Over the past 2 decades, there has been a significant increase in life span of patients with cancer so that now, there are more than 10 million cancer survivors in the U.S. [1]. There is a growing recognition that although survival has improved, many long-term side effects including cardiac complications limit quality of life and life span after cancer. Additionally, cardiac disease remains one of the most common illness affecting all patients, including those with cancer. As a result, there is a mandate from the Institute of Medicine to improve the recognition and treatment of side effects for cancer survivors [2]. The primary goal of this clinical research study is to determine if biomarker testing can help to detect early heart damage that may occur during anthracycline chemotherapy. Biomarkers are chemical markers found in the blood and can be released in response to cardiac injury. Additional secondary objectives are to define the sensitivity and specificity of echocardiography for the detection of cardiotoxicity and determine the natural history of anthracycline cardiotoxicity in patients identified as high risk via biomarkers. We will also explore genetic factors that may be associated with increased cardiotoxicity.

You may be eligible for this study if you meet the following criteria:

• Conditions: biological markers, cardiotoxins, anthracyclines
• Age: 1 years - 99 years
• Gender: All